OpenLobby.EU
Explore

All.Can International

All.Can International is a global, multi-stakeholder initiative to inform and generate political and public engagement on the need to improve the efficiency of cancer care, by focusing on what really matters to patients and the society.

Lobbying Activity

Response to EU cardiovascular health plan

15 Sept 2025

Daiichi Sankyo is an innovative global healthcare company with more than 120 years in research, development and manufacturing of innovative medicines. We are leaders in cardiovascular care and remain committed to advancing treatments across the health continuum. Daiichi Sankyo welcomes the European Commissions initiative and believes the Plan should prioritise the following areas: 1. Tap into existing EU funds to invest in the implementation of simple and cost-effective routine CV health checks at primary care level. Streamline EU funding to sustain innovation through existing (Horizon Europe) or upcoming (Competitiveness Fund) programmes. Cardiovascular disease remains the leading cause of morbidity and mortality across Europe, with 13 million new cases diagnosed each year and 5,000 lives lost daily , with an estimated economic cost of 282 billion annually including direct and indirect costs in terms of lost productivity . While population-level measures that promote healthy lifestyles remain essential, primary prevention alone is not enough for people who are already at high risk, living with comorbidities or having a genetic predisposition to CVD. Early identification of CV risk is crucial to reducing complications, comorbidities and premature deaths, and could lead to the prevention of 1 million European fatalities per year . In that regard, the Plan should: Support a shift from opportunistic to systematic, routine CV screening encompassing both primary and secondary prevention by means of Cardiovascular Health Checks across EU Member States for all adults. Support sharing of best practices between Member States to ensure efficient implementation of these health checks at national level through a Council Recommendation; 2. The EU CVH Plan should promote equitable access to high-quality prevention, screening, and treatment across Europe, addressing existing regional and gender disparities throughout the life course. Compared with men, women are up to 50% more likely to be misdiagnosed during a heart attack, experience higher mortality, face substantial barriers to timely diagnosis and treatment, and remain under-represented in CV research . As revealed through our SANTORINI study, women are less likely to receive lipid-lowering therapies and achieve LDL cholesterol goals. In that regard, the Plan should: Address regional inequalities by: o Establishing an Inequalities Registry for CVD, implemented by the Joint Research Centre and bringing together existing cardiovascular registries, building on the success of the Europes Beating Cancer Plan to enable identification of best practices Address gender inequalities by embedding measures to: o Promote robust, sex-disaggregated data collection to monitor progress. o Include pilots for CV screening in high-risk women. o Strengthen professional medical education on sex- and gender-specific conditions. 3. The Plan should embed a patient-centred, life-course approach, seeking to improve the patient journey through enhanced disease management, including therapeutic adherence. Empowering patients in decision-making, tailoring therapy to individual risk profiles, and providing continuity of care improves adherence to treatment. In turn, improved adherence prevents treatment discontinuation and delivers better outcomes for both patients and health systems. The Plan should: Support the development of a European network of integrated CVH centres of excellence across the EU Member States Support Members States to implement adherence programs through a new generation of patient-centred disease management programmes in chronic CV groups, 4. The EU CVH Plan should invest in innovation and enable digital health solutions to improve clinical outcomes. Daiichi Sankyo believes that - as demonstrated by our DSPACE program - better use of digital tools can improve improve earlier diagnosis, access to treatment, continuity of care and patient self management.
Read full response

Response to Cancer Screening Recommendation

18 Feb 2022

All.Can welcomes the opportunity to respond to the European Commission’s call for evidence to update the EU Cancer Screening Recommendation. All.Can is a global, non-profit, and multi-stakeholder organisation aiming to drive measurable improvements in cancer care efficiency, to ensure equitable access to quality care for patients while contributing to healthcare systems’ sustainability. For All.Can, efficient cancer care delivers the best possible health outcomes using the human, financial, infrastructural and technological resources available, with a focus on what really matters to patients and to society. Efficiency is driven by promoting early and accurate diagnosis through 2 levers: - Primary care, evidence-based screening, diagnostic capacity, effective referral - Personalised risk grouping and screening Accordingly, All.Can fully supports the Europe’s Beating Cancer Plan and the new EU Cancer Screening Scheme to reinforce Member States’ diligent screening of European citizens who would benefit from it. We appreciate the Commission’s ambition to extend screening to other types of cancers including lung, prostate and gastric cancers. Screening programmes may be considered efficient if they help reach populations at highest risk of cancer, enable earlier diagnosis and improve outcomes – therefore, it is crucial to develop a robust evidence base to inform which population groups should be targeted, and refine the methodology and technology to deliver them. In our 2019 patient survey, around 1/4 respondents singled out initial diagnosis as the area of cancer care where they experienced most inefficiency. 32% of respondents whose cancer was detected outside of a screening programme reported that it was first misdiagnosed as something else: this rate was 41-51% for gastric, sarcoma, head and neck, colorectal/bowel and gynaecological cancers. Late diagnosis and misdiagnosis can delay or limit treatment, causing poorer outcomes, a lower likelihood of survival, and higher care costs. A delay as short as 4 weeks increases mortality from various common cancers, with longer delays being increasingly detrimental. Rare forms of cancer are particularly likely to be diagnosed late or misdiagnosed. Prompt and accurate diagnosis is thus pivotal to efficiency, and we recommend that decision-makers focus particularly on: - strengthening evidence-based screening programmes that play a vital role in the early detection of some cancers (especially cervical, breast and colorectal cancer), while noting that patients’ access to these measures varies and COVID-19 has disrupted many programmes - extending the EU Cancer Screening Recommendation to lung cancer in light of the substantial impact of late and misdiagnosis and the evidence of benefit, as advocated by the European Respiratory Society, All.Can and other major cancer organisations - investing in technologies and diagnostic capacities, including relevant primary care services, mobile units, tests, imaging, laboratories, and staff - investing in research exploring other innovative and promising approaches, including the use of artificial intelligence and machine learning to improve the early detection of cancers - improving cancer health literacy among the public through campaigns at the national level that involve healthcare professionals to communicate the benefits of screening to patients. Ultimately, decision-makers must also address socioeconomic factors that can contribute to late diagnosis (e.g. out-of-pocket costs). Making screening more accessible also means addressing inequities among countries and regions, and ensuring, for example, equal access to prevention opportunities for women affected by cancer. There should be synergy among all European Commission initiatives addressing inequalities, and coordinated action across Member States is needed to prioritise access and allocate adequate funds to cancer screening in national cancer plans.
Read full response

Response to A European Health Data Space

3 Feb 2021

All.Can welcomes the European Health Data Space (EHDS) initiative which seeks to ensure access and optimal use of health data as well as digital health products and services. Efficient healthcare systems that deliver the best possible outcomes for patients are evidence-based learning systems that incorporate meaningful input from healthcare users, make continuous assessments of products and processes, and report the results of healthcare interventions transparently. Robust data collection is a key driver to ensure that inefficiencies are systematically identified and remedied and health outcomes are continuously improved for the benefit of patients and their families. In cancer care, systematic and holistic reporting of robust data is vital to create a cycle of continuous improvement and drive accountability across the entire care pathway. For a comprehensive EHDS that can help realise this goal and importantly, has patients’ needs at its core, All.Can calls attention to the following challenges and proposed recommendations to address them. - Data quality: Low quality and unreliable data often limits the ability to impact decision-making across cancer care and damage the trust of stakeholders. o Applying various tools and techniques to improve data quality and strengthening quality control mechanisms can help generate and maintain high-quality datasets. - Data representativeness: Data not representative of entire populations result in inequities, hampering access to timely diagnosis and high-quality treatment. o Promoting collection of equitable and representative data is key to ensuring that all patient populations benefit equally from healthcare improvement efforts. - Data relevance: Data collected in our healthcare systems are often not patient-centred or aligned with patient values. o Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) data should be systematically collected and analysed to guide quality improvement efforts. - Data silos and interoperability: Data silos and poor interoperability of datasets hinder the measuring of healthcare services performance, and linking of health data across the care pathway for secondary uses. o Creating national and international data standards fosters database linking, through improved data standardisation and interoperability of key national health datasets. - Healthcare professional buy-in: Cooperation from healthcare professionals is key to continuous collection, use and sharing of clinical data. o A positive culture of data sharing should be promoted among healthcare professionals through incentives, including minimising the burden of data collection by streamlining, integrating and standardising data collection systems. - Building trust: Lack of trust and transparency coupled with burdensome data collection systems disincentivise sharing of data. o Initiatives to build public trust in data and data sharing should be fostered. The burden of data collection on individuals should be mitigated to boost participation in data collection efforts. - Data governance: Countries remain slow in adapting approaches to harness big data in health, due to governance-related barriers such as gaps in funding, leadership, technical expertise and competing priorities within the health systems. o Strong data governance frameworks that can facilitate effective data collection, use and sharing should be developed, with attention to privacy confidentiality, privacy and security for system users. - Data analytics: There remains an unmet need in providing better linkages between health information systems and big data analytics that can transform healthcare by helping to extract insights from vast amounts of data. o To facilitate primary and secondary uses of data and tap into the potential of wide-ranging applications of AI and machine learning, countries should invest in data analytics and their integration in care pathways.
Read full response